$AME

AMETEK INC/ (AME): Entry into a Material Definitive Agreement

AMETEK INC/ (AME) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 exhibit101jpm-ametekxcredi.htm EX-10.1 Document Exhibit 10.1 EXECUTION COPY AMENDED AND RESTATED CREDIT AGREEMENT dated as of September 22, 2011 as amended and restated as of March 10, 2016 as further amended and restated as of October 30, 2018 as further amended and re

Original reporting
Published Jun 12, 2026, 6:58 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 6:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$AME
Neutral
medium confidence
Mentioned
$AME
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AMENeutralLow
01

Why it matters

Updating a credit agreement can change liquidity access and the company’s financing cost/covenant posture; however, the excerpt does not provide the economic terms needed to quantify impact.

02

Market read

Primary SEC filing confirms AMETEK’s updated financing arrangement; without disclosed pricing/covenant details, expected equity reaction is modest.

03

What to watch

Traders should verify the final agreement for any changes to leverage/covenant thresholds, maturity extension, incremental borrowing capacity, or benchmark/interest-rate mechanics—those details would determine whether the credit risk profile improved or worsened.

Relevance 6/10Novelty 4/10Timing: filed June 12, 2026 (8-K)

Background

The 8-K attaches an amended and restated credit agreement dated Sept. 22, 2011, repeatedly amended/restated through June 9, 2026, among AMETEK, foreign subsidiary borrowers, and a syndicate of major banks.

Company-level read

Ticker impact

$AMENeutralMedium confidence
Context

AMETEK filed an 8-K for entry into an amended and restated credit agreement, creating/adjusting direct financial obligations.

Expected impact

Likely limited immediate equity impact; any move would be driven by changes in credit spreads, maturity, or covenant headroom not shown in the excerpt.

Evidence & confidence

This is a primary SEC disclosure (8-K) tied to a material definitive agreement, but the provided text is largely boilerplate contract structure without key economic terms (rates, size, maturity, covenants) to gauge magnitude.

Market effects

Credit-facility amendments are typically company-specific; limited read-across to industrials unless terms indicate sector-wide stress (not evidenced here).

None indicated; lenders are global banks but no regional macro linkage is described.

Minimal; the agreement references foreign subsidiary borrowers but no cross-border shock or sanctions/regulatory trigger is disclosed in the excerpt.

Counterpoint

Because the excerpt doesn’t show facility size, pricing, maturity, or covenant changes, the market may treat this as routine refinancing/administrative restatement rather than a fundamental credit event.

Key entities

  • AMETEK, INC.

    Company entering a material definitive agreement via an amended and restated credit agreement (8-K Item 1.01 / Item 2.03).

  • JPMorgan Chase Bank, N.A. (and J.P. Morgan SE)

    Administrative agent named in the credit agreement.

  • Bank of America, N.A.; PNC Bank; Truist; Wells Fargo; U.S. Bank; BNP Paribas; Commerzbank; The Bank of Nova Scotia; Citizens Bank; ING Bank Dublin

    Co-syndication and documentation agents listed in the agreement excerpt.

Related articles

$AMEMed

Segment Demand and Strategic Acquisitions Propel Growth

AMETEK (NYSE: AME) reported Q2 CY2026 revenue of $2.04 billion, up 15% year over year, beating Wall Street expectations. Non-GAAP EPS was $2.09, 4.8% above consensus. Management cited organic growth, rising orders and backlog of $4.11 billion, and contributions from acquisitions. Full-year guidance was raised, supported by AI, defense, and power grid demand.

$AMEMedAI 8/10

AMETEK, Inc. Q2 2026 Earnings Call Summary

AMETEK reported Q2 2026 momentum driven by multi-year infrastructure build-outs for AI, semiconductors, and power. Organic sales growth accelerated, with a record $4.11B backlog and about 80% expected to ship in 12 months. Core EMG margins rose 290 bps. Full-year 2026 organic sales guidance was raised to mid-to-high single digits; Indicor Instrumentation acquisition of $5B expected to close in H2 with 10% to 12% synergies.

$AMEHigh

AMETEK INC/ (AME): Results of Operations and Financial Condition

AMETEK INC/ (AME) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ametek8kexhibit99108042026.htm EX-99.1 Document Exhibit 99.1 AMETEK Announces Record Second Quarter 2026 Results and Raises Full Year Guidance Berwyn, Pa., Aug 4, 2026 – AMETEK, Inc. (NYSE: AME) today announced its financial results for the second quarter ended June 30,

$AMEMedAI 8/10

AMETEK’s (NYSE:AME) Q2 CY2026: Strong Sales

AMETEK (NYSE:AME) reported Q2 CY2026 revenue of $2.04 billion, up 15% year on year, exceeding Wall Street estimates by 4.4%, according to the company. Non-GAAP adjusted EPS was $2.09, up from $1.78 and 4.8% above consensus. Analysts expect full-year EPS of $8.46, up from $7.96.

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.